XBI State Street SPDR S&P Biotech ETF
Trend channel, buy level and 3-month target. Information only, not financial advice.
Below the channel · 9-month channel rising
Closed below support (US$164.78). Treat the buy level with caution.
- 9-month channel read from
- US$164.78 – US$188.80 · rising, +47% a year
- 12-month channel
- US$164.33 – US$176.07 · rising, +42% a year
- Price in channel
- −37% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$176.07
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 12:42 PM ET (71 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy now
US$155.96
last close · 30 Oct 2026
Our target
US$176.94
by 26 Jan 2027
Projected move
13.5%
gross, before costs
Last close is our buy.
Target: XBI's usual move size.
This move size: reached in 38% of 21 past stretches, typically in 87 days. (0.14% per day)
- Upper line touches
- 3
- Lower line touches
- 3
- Fit confidence
- 67%
- Fitted
- 1 Nov 2026
Company information
About State Street SPDR S&P Biotech ETF
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
- Sector
- Financial Services
- Industry
- Asset Management
- Country
- US
https://www.ssga.com/us/en/intermediary/etfs/spdr-sp-biotech-etf-xbi
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$7.83B
- Enterprise value
- —
- Beta
- 1.10
- Avg volume
- 9.17M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 106.3-169.89
- Exchange
- AMEX
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.